{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:15:10Z","timestamp":1788434110512,"version":"build-2803163510"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100000062","name":"National Institutes of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5T32DK007135-46"],"award-info":[{"award-number":["5T32DK007135-46"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.2215\/cjn.14201021","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T12:20:24Z","timestamp":1644322824000},"page":"581-584","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Syndromes of Pseudo-Hyperaldosteronism"],"prefix":"10.2215","volume":"17","author":[{"given":"Katherine","family":"Rizzolo","sequence":"first","affiliation":[{"name":"Department of Nephrology, University of Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"Ambruso","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Colorado, Aurora, Colorado"},{"name":"Nephrology Division, Rocky Mountain Veterans Affairs Medical Center, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1053\/j.ajkd.2010.07.010","article-title":"A physiologic-based approach to the evaluation of a patient with hypokalemia","volume":"56","author":"Palmer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.1993.00410180075008","article-title":"The diagnosis of primary aldosteronism and separation of two major subtypes","volume":"153","author":"Weinberger","year":"1993","journal-title":"Arch Intern Med"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00004872-200305002-00005","article-title":"Investigating mineralocorticoid hypertension","volume":"21","author":"Nussberger","year":"2003","journal-title":"J Hypertens Suppl"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fendo.2019.00484","article-title":"Licorice: From pseudohyperaldosteronism to therapeutic uses","volume":"10","author":"Sabbadin","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"105605","DOI":"10.1016\/j.jsbmb.2020.105605","article-title":"Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals","volume":"199","author":"Beck","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/eje.0.1490163","article-title":"Tissue-specific Cushing\u2019s syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action","volume":"149","author":"Stewart","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncologist"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ctrv.2013.03.003","article-title":"Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone","volume":"39","author":"Pia","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/j.clgc.2016.12.008","article-title":"Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration-resistant prostate cancer treated with abiraterone without prednisone","volume":"15","author":"Gill","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000477547","article-title":"Amiloride is effective in the management of abiraterone-induced mineralocorticoid excess syndrome without interfering with its antineoplastic activity","volume":"100","author":"Bedussi","year":"2017","journal-title":"Pharmacology"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14201021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:31Z","timestamp":1786369471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14201021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.14201021","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}